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This strategy document begins in Chapter 1 
by outlining in lay terms:
i)   how the kidneys perform in health and 
disease;
ii)  who is affected by kidney disease; and
iii)   what constitutes the current spectrum of 
renal research
We follow in Section 1.2 by summarising the 
organisational components involved with 
and supporting this research, by outlining 
the main funding bodies and by charting in 
Section 1.3 the current strengths of UK renal 
research. 
Chapter 2 uses information gathered from 
a preliminary round of consultation, firstly 
to detail the renal community’s expressed 
priorities for UK renal research and secondly, 
based on these priorities, to ascertain the 
main evidence gaps.
In Chapter 3 we make a series of 
Recommendations for maximising our 
successes and addressing these priorities 
while overcoming the challenges associated 
with research in the 21st century.
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Foreword
Human health cannot improve without 
research, which forms the basis both for the 
understanding of diseases and for the delivery 
of better healthcare. Kidney disease affects 
several million people in the UK, and can have a 
devastating impact on the lives of patients, their 
families and carers.
I am therefore delighted to welcome the UK’s 
first comprehensive Renal Research Strategy. It 
is an ambitious yet realistic document and one 
that, in time, deserves to effect a step change 
in renal care - an area that historically has been 
somewhat neglected. 
As Minister for Life Sciences, my principal 
motivation is to ensure that the NHS is equipped 
to be the global leader in the latest medical 
innovations and healthcare technologies. In 
this role I have had the privilege to see how 
our scientists, researchers and clinicians are 
pioneering ground-breaking approaches and 
achieving staggering breakthroughs. I am 
confident the Accelerated Access Review (AAR) 
will provide a sense of how we can make sure all 
of this is carried out with the single aim of finding 
new and improved ways of treating and caring for 
patients and enhancing their health and quality 
of life. 
But I have also heard from all sectors of the 
research community about the challenges facing 
their critical part of the equation. At the heart of 
the AAR are some key questions: “how can the UK 
continue to be an attractive environment both 
for research and for seeing results translated into 
practice?” and “what are the levers that will help 
transform patient experience and the way our 
NHS works?” 
That is why I am so encouraged 
to see the renal community come 
together, reflect on these challenges 
and set out clear research themes, 
research priorities and enablers. 
Its focus on the full spectrum, from 
research in the laboratory all the way 
to kidney patients and their carers, is 
intended to support the design, delivery 
and dissemination of sustainable high 
quality programmes of work.  
This document provides an invaluable 
starting point, from which we can ensure 
that the UK’s renal health sector is 
recognised as a global beacon of excellence. 
I look forward to continuing working with the 
renal community to facilitate the Strategy’s 
delivery and its alignment both with the AAR 
and the Government’s broader policy agenda.
George Freeman MP,  
Parliamentary Under Secretary  
of State for Life Sciences
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Executive summary
•  This document is intended both to unite 
the whole renal professional and patient 
community and to provide information and 
evidence for funders, policymakers and 
those helping to create and support the next 
generation of researchers.
•  Kidney disease in its many forms affects 
several million people in the UK, and in its 
more severe manifestations has devastating 
impacts on the lives of patients, their families 
and carers. 
•  Research is an essential driver of 
improvements in all human health, forming 
the basis for the understanding of disease, for 
development and roll-out of new therapies, 
for the delivery of better healthcare and for 
preventative strategies.
•  This first UK Renal Research Strategy 
highlights areas where we believe  
investment and collaborative efforts will  
have maximum impact to benefit the health 
and welfare of kidney patients and those at 
risk of kidney disease.
•  These Aims and Recommendations are not 
intended to be a ranked list.
•  A Steering Group comprising a representative 
from each of the major renal stakeholder 
organisations developed this document,1 and 
two rounds of widely-based consultation 
were undertaken. Thus a wide cross-section 
of interested parties including patients, 
clinicians,2 multi-disciplinary teams, 
researchers and funders contributed to the 
strategic vision described here.
•  Concerted action from many parties over 
the next five to ten years will be needed 
to realise these Aims. We have highlighted 
what we as a kidney community believe to 
be the key research themes, priorities and 
enablers to support the design, delivery and 
dissemination of sustainable high quality  
programmes of work. 
•  We recognise that funding for research can 
never stretch to cover all aspirations. Within 
the document, each Recommendation is 
accompanied by a description of the related 
issues, followed by one or more possible ways 
forward. Some are short-term, while others 
look very much to the longer-term; some can 
be achieved by the renal community working 
together (e.g. Recommendations 1,2,4,7,8), 
while others (e.g. 3,5,6,9-13) will require 
external input and contributions. 
•  Progress will need to be monitored and 
reviewed by an Implementation Board, 
preferably under the UK Kidney Research 
Consortium umbrella and including 
representation of the full renal researcher 
spectrum, with formal review after two years.
•  Our Recommendations are set in the context 
of what has been achieved over many 
decades, and we believe they will present 
good opportunities for advancement in the 
future. The Steering Group would like to take 
this opportunity to celebrate and commend 
the kidney community’s long-standing 
commitment to improving the lives of people 
with kidney disease.
1  Steering Group: See members listing on inside front cover
2  Includes surgeons, paediatricians and medical specialists
Strategic Aim 2 
Capitalise on the full spectrum of research approaches to ensure 
a well-balanced portfolio that includes underlying mechanisms, 
prevention, treatment and impact. 
Recommendation 5:
Preserve support and funding 
of laboratory science, 
because new fundamental 
discoveries are the key to future 
improvements in health.
Recommendation 6:
Increase the number and quality 
of clinical trials, to address 
evidence gaps and measure  
and determine best  
practice/treatment. 
Recommendation 7:
Embed commitment to robust 
and appropriate patient-focused 
and patient-led qualitative 
research, to allow improvements 
in quality of care, health, quality of 
life and patient empowerment.
Recommendation 8:
Build the evidence base 
(improvement science) that will 
reduce unwarranted variation in 
practice and increase equitable 
access for patients to the best 
available treatment. 
Strategic Aim 1
Increase engagement of professionals, patients and the public with 
kidney research. 
Recommendation 1:
Develop a culture where every 
person with a renal disorder3 
accessing any type of renal 
service (or their families and 
carers, where appropriate) 
is offered the opportunity to 
participate in research. 
Recommendation 3:
Create a national Kidney 
Biobank for collection and 
storage of biological samples 
from every kidney patient, to 
provide a strategic resource for 
fundamental and translational 
research. 
Recommendation 2:
Increase and promote equitable 
access to research for minority  
groups with kidney disorders, 
including children and those  
from Black, Asian and Minority 
Ethnic backgrounds.
Recommendation 4:
To complete the research 
loop, better communicate the 
outcome of all kidney research 
to patients and the public in 
accessible language that they 
can understand.
3 The terms ‘kidney’ and ‘renal’ are used interchangeably throughout, as are ‘nephrology’ and ‘renal medicine’
Our aims
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Strategic Aim 4 
Create a more open research culture to maximise cross-disciplinary 
and collaborative research.  
Strategic Aim 3 
Support the research training and career development of all contributors 
to renal research, to build sustainable research capability and capacity. 
Recommendation 11:
Strengthen formal partnerships 
across disciplines, patient 
groups, professional bodies and 
charities aligned with kidney 
disease, particularly in diabetes 
and cardiovascular disease.
Recommendation 9:
Increase resources and 
mentorship to develop and 
maintain research skills  
among all health professionals, 
to ensure high quality  
multi-disciplinary renal research. 
Recommendation 12:
Build closer research links 
with industry to identify new 
therapeutic targets, develop 
collaborative clinical trials 
and increase research funding 
opportunities. 
Recommendation 13:
Work collectively towards 
a simpler, faster and more 
responsive pathway to ethical 
and regulatory approval, 
particularly for low-risk projects. 
Recommendation 10:
Improve support, training  
and career paths for  
non-clinical renal scientists  
in the academic sector. 
UK Renal Research Strategy     5
ages the kidneys may be ‘innocent bystanders’ damaged by 
side-effects of drugs administered for a wide range of other 
disorders, or by circulatory failure triggered by disease (such 
as heart or liver failure) or massive blood loss elsewhere in the 
body (e.g. during surgery). In addition, 
up to 12% of those attending  
renal units have a rare cause  
of their kidney problem 
(defined as affecting fewer than one in 2,000 people). The 
spectrum of such disorders is huge, ranging from those that 
are life-limiting in early life to those where excretory renal 
function is unlikely to be affected but homeostatic  
processes (the body’s ability to maintain internal stability)  
have gone awry.
Chronic kidney disease (CKD) is the term conventionally 
applied to abnormalities of kidney structure or function that 
are present for more than three months and have implications 
for health. 
Disorders of the kidneys and urinary tract may occur across 
a spectrum ranging from serious structural abnormalities 
or complete failure to produce urine to disturbances in the 
balance of one or more substances in the body for which the 
kidneys are responsible, but which leave excretory function 
intact. Minimally damaged kidneys often have no significant 
impact on wellbeing; poorly functioning kidneys may still be 
able to sustain life, but at the expense of chronic ill health 
including high blood pressure, anaemia, bone disease  
(causing fractures and, in children, poor growth) and a  
marked propensity to heart attacks and strokes.
Many different disease processes can affect the kidneys. 
Young children with renal failure are often born with abnormal 
kidneys and some of them carry mutations in genes that 
control normal kidney growth, maturation and function. By 
contrast, most kidney failure in older children and adults is 
caused by damage to previously normal kidneys, and may be 
due to immunological factors (glomerulonephritis); infections 
(often originating in an abnormal lower renal tract); diabetes; 
or the overgrowth of tubules (in polycystic kidneys).4,5 At all 
1.1.2  Kidney disease, kidney patients and their care
1.1 Introduction
1.1.1   Introducing the kidneys in health and disease
The urinary system is crucial for life. It consists of the kidneys and lower renal tract (the 
ureters, bladder and urethra). This complex set of structures works in harmony to fulfil three 
main functions:
To carry out these various functions, the kidneys contain many 
different types of cell. The kidneys begin to form during the 
first three months of pregnancy, and even after birth they 
continue to grow and mature. Without kidneys a person would 
die within a few days to weeks as a result of the build up of 
waste products and fluid. From approximately age 30, there 
is a natural subtle but progressive decline in kidney function 
that does not usually impair health, but which may make the 
kidneys less able to cope with disease. 
the production and passing of urine 
as a vehicle for the excretion of 
metabolic waste products, at the 
same time retaining cells and useful 
proteins within the circulation;
4 Finne P et al JAMA 2005;294:1782 5 de Boer IH et al J Am Soc Nephrol 2014; 25:2342-50
Chapter 1 
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maintaining normal bodily  
balances of water and many  
different molecules and minerals 
(such as sodium, potassium  
and calcium); 
and the production of hormones  
that play roles in blood pressure 
control and the formation of  
red blood cells. 
1 2 3
CKD is common - up to 
of the UK adult  
population may be affected
6
 - and is frequently unrecognised. It  
commonly co-exists with diabetes and cardiovascular disease. 
A small but important minority of people with CKD will 
progress to 'end stage kidney disease', where regular dialysis 
treatment or kidney transplantation are needed to sustain life. 
Cardiovascular risk is increased in CKD, even in the earlier 
stages, and much more so in the dialysis population. Robust 
epidemiological (population-level) data demonstrate that 
reduced excretory function and the presence of protein in the 
urine are powerful independent risk factors for cardiovascular 
disease across a range of populations.8 People with CKD may 
also be vulnerable to harm as a result of poor prescribing. 
There are also important associations between CKD, 
depression⁹ and frailty.10 
Acute kidney injury (AKI), formerly called ‘acute renal failure’, 
is characterised by the abrupt impairment of kidney function. 
Existing CKD is a critical risk factor for AKI. AKI is associated 
with 20% of emergency hospital admissions and a mortality 
rate in hospital In-patients of nearly 24%.11 It is also  
common postoperatively. 
Kidney disease does not affect all populations equally. Black 
and South Asian patients are over-represented, particularly 
in the most severe stages of disease. CKD is associated with 
lower socio-economic status, and people from more  
socially deprived areas have poorer access to the  
transplant waiting list.14 
1.1.3 Kidney research
The complex biology of normal kidneys  and the very wide 
spectrum of renal disease makes Nephrology both a potentially 
challenging but also a highly rewarding specialty. The same 
complexity is reflected in the variety of research being 
undertaken to better understand how the kidney works in 
health and disease, and how best to meet the needs of kidney 
patients of all kinds. This spans trying to understand how 
kidneys grow, how they respond to injury, and how best to treat 
people with established kidney disease. 
Understanding renal pathophysiology and the implications for 
patients has therefore been the subject of a wide spectrum of 
scientific approaches. These have interested researchers with 
primary backgrounds in molecular, cellular, whole organism 
and population-based techniques, and have included both 
quantitative and qualitative methodologies. 
The renal research community encompasses a wide range of 
both academic (i.e. university-salaried) and clinical (employed 
by the NHS) investigators. The main pockets of excellence in 
‘pre-clinical’ research have traditionally been based in the 
major UK Russell Group Universities. 
They are renowned for world-leading  
basic science, and the UK has a strong 
international track record in genetics, 
molecular and biochemical mechanisms and  
animal studies in a range of renal disorders. 
However, the geographical distribution of renal research has 
widened over the past decade. The synergy of pre-clinical and 
clinical approaches has resulted in various high-impact clinical 
trials, and the engagement of different members of the multi-
professional team has ensured that Nephrology has long been 
perceived as an exciting academic specialty and as such has 
attracted generations of trainees. 
People with kidney disease and  
their families are essential  
partners in research, and the  
power of the patient voice  
must not be under-estimated. 
This was exemplified in the creation of the Kidney Health: 
Delivering Excellence report published in October 2013,15 which 
was co-written by patients and professionals. It articulated 16 
future ambitions for kidney care, several of which call for better 
evidence to support the delivery of high-quality care. The need 
for a UK renal research strategy was highlighted in Ambition 
15; this document is the renal community’s response to that 
call, within which the patient’s voice, research preferences and 
priorities have been sought and embedded.
6  https://catalogue.ic.nhs.uk/publications/public-health/surveys/ 
heal-surv-heal-life-eng-2009/heal-surv-heal-life-eng-2009-rep-v2.pdf 
7  https://www.england.nhs.uk/wp-content/uploads/2014/04/ 
a07-renal-transpl-ad-0414.pdf
8  Nitsch D et al BMJ 2013; 346:f324; Fox CS et al Lancet 2012;380:1662–73; 
Matsushita K et al Lancet 2010;375:2073–81
9 Palmer S et al Kidney Int 2013;84:179–191
10 Walker SR et al BMC Nephrol 2013;14:228
11 Selby NM et al CJASN 2012;7:533
12 Kerr M et al Nephrol Dial Transplant 2014;29:1362
13 http://www.ncepod.org.uk/2009aki.html
14 Udayaraj UP et al J Epidemiol Community Health 2010;64:535-41
15  http://www.britishkidney-pa.co.uk/images/stories/downloads/ 
Kidney-Health-Report.pdf
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The annual cost of  
AKI-related in-patient  
care in England is  
estimated at over
£1 billion
just over 1%  
of the NHS  
budget.12 
 
of cases are thought 
to be predictable 
and avoidable.13
haemodialysis 
costs the NHS  
at least
£30,000
per patient  
per year.⁷
In the UK, about
800 
children and
57,000  
adults 
are in this situation;
20% 
13%
1.2. Organisational components of UK renal research
Renal research in the UK is underpinned by a variety of professional and patient organisations 
and funding streams that often overlap. These are listed below and a description of each can 
be found in Appendix 1.
B. Main funders
• Kidney Research UK (KRUK)34   
• Kids Kidney Research (KKR)35 
• British Kidney Patient Association (BKPA)20
• British Renal Society (BRS)18
•  Other charitable research funding bodies e.g. 
Wellcome Trust,36 British Heart Foundation37  
and the Royal College of Surgeons38 
• Medical Research Council39 
• National Institute for Health Research (NIHR)40 
• The Health Foundation41 
•  Chief Scientist’s Office Scotland and  
NHS Research Scotland42  
• Industry
• The European Union43 
16 http://www.renal.org
17 http://www.renal.org/bapn
18 http://www.britishrenal.org
19 http://www.bts.org.uk
20 http://www.britishkidney-pa.co.uk
21 http://www.kidney.org.uk
22 http://pkdcharity.org.uk/home
23  https://www.kidneyresearchuk.org/ 
action-for-alports
24 http://ahusuk.org
25 http://www.nbta-uk.org.uk 
26 http://www.renal.org/about-us/what-we-do/ 
joint-activities/uk-kidney-research-consortium
27 http://www.crn.nihr.ac.uk/renal
28 https://www.renalreg.org
29 http://www.rarerenal.org and 
http://rarerenal.org/radar-registry
30 http://www.nhsbt.nhs.uk
31 http://kidneyresearchunit.wales/en/
32  http://www.research.hscni.net/sites/default/ 
files/Renal_Leaflet_10_12.pdf
33  http://www.nhsresearchscotland.org.uk/ 
research-areas/renal
34 http://www.kidneyresearchuk.org
35 http://www.kidskidneyresearch.org
36 http://www.wellcome.ac.uk
37 https://www.bhf.org.uk
38  https://www.rcseng.ac.uk/surgeons/ 
training/fellowships
39 http://www.mrc.ac.uk
40  http://www.nihr.ac.uk
41 http://www.health.org.uk
42  http://www.cso.scot.nhs.uk and  
http://www.nhsresearchscotland.org.uk
43 https://erc.europa.eu
A.  Professional and patient 
organisations
• The Renal Association16  
•  The British Association for Paediatric Nephrology 
(BAPN)17  
• The British Renal Society (BRS)18  
•  The British Transplantation Society (BTS)19  
•  Patient organisations 
a)  The British Kidney Patient Association (BKPA)20  
b)  The National Kidney Federation (NKF)21  
c) Many individual diagnosis-specific charities as well 
as patient/family support groups including  
The PKD (Polycystic Kidney Disease) Charity,22   
Action for Alports23 and Atypical Haemolytic  
Uraemic Syndrome (aHUSUK)24 
d)  The National BAME (Black, Asian and Minority 
Ethnic) Transplant Alliance (NBTA)25  
•  The UK Kidney Research Consortium (UKKRC)26  
•  The National Institute for Health Research (NIHR)  
Clinical Research Network (CRN) Renal Disorders  
Specialty Group27  
• The UK Renal Registry (UKRR)28  
•  Rare disease working groups and registry (RaDaR)29  
• NHS Blood and Transplant (NHSBT)30 
•  Devolved nations 
a) The Wales Kidney Research Unit31
b)  The Northern Ireland renal Clinical  
Research Network32 
c) NHS Research Scotland33 
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1.3  The impacts of UK renal research
The UK Renal community has a long tradition of research in 
combination with clinical care. 
A key feature of this research has  
been the wide range of topics  
studied, which covers the  
spectrum from pre-clinical  
‘laboratory’ research to  
patient-focused ‘clinical’ research. 
For the latter, research has generated a significant evidence 
base for patient care, including treatment delivery, workforce 
planning, nutrition and exercise counselling, models of shared 
and self-care, psychosocial and psychiatric care, behaviour 
change, patient education, treatment choices, and patient-
shared decision making. Such studies have directly informed 
National Institute of Health and Clinical Excellence guidelines, 
and continue to do so.44  There are also strong examples 
in clinical trials, epidemiology and, at the ‘laboratory’ end, 
understanding normal and disease implications of genetics, 
developmental and cell biology, immunology, and physiology.
Often, both laboratory-based  
and clinical research can be  
enhanced by inputs from more  
than one individual, team,  
organisation or approach. 
The NIHR CRN provides the infrastructure to support clinical 
trial activity and successful coalitions of professional and 
patient groupings highlight the capacity for UK kidney 
community collaboration. For example, the harmonious 
interaction of UKKRC, Kidney Research UK and the NIHR Renal 
Disorders group has led to an excellent model within which 
research developments (the Clinical Study Groups (CSGs)) and 
delivery (NIHR) are flourishing.45   
We are also beginning to see better integration of clinician 
with non-clinician academics, and of renal researchers with 
industrial partners. In addition, 
the Renal Registry offers  
a potential wealth of  
routine healthcare data  
for researchers.
Together with the recognised strengths of UK basic science 
research and a strong academic pedigree within renal 
medicine, all these elements create a fertile environment for 
world-class research.
We began the process of  
formulating this strategy  
document by asking a wide  
range of stakeholders to provide  
examples of recent research  
that they consider have had  
(or will have) the most impact. 
While a complete list is beyond the scope of this document, 
the responses received included a number of notable  
research studies in which the UK has led the way, which are 
presented in Appendix 2 and which sit within the  
following areas:
44  Examples include CG182 (Early identification and management of chronic kidney disease in adults in primary and secondary care),  
CG157 (Phosphate binders in adults), NG8 (Anaemia management in people with CKD).
45  UK Kidney Research Consortium. Clin Med 2015;15:415-9
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1
4
2
5
3
Drugs and interventions to treat 
CKD and its complications
Care of people with CKD  
prior to and on dialysis
The biology of renal diseases
Kidney transplantation
Genetic causes of renal disease
Chapter 2 
In this chapter, we first summarise 
the research priorities that were 
identified by consulting a wide 
range of stakeholders comprising 
renal professional bodies, renal 
research charities and representative 
patient charities and organisations. 
Secondly, we have collated the 
major evidence gaps identified by 
stakeholders themselves. In Chapter 
3 we distill these into a set of major 
goals and propose strategic ways to 
achieve them.
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2.1 Research priorities
2.1.1 The patient view
As described in Chapter 1 and Appendix 1, in the UK the 
patient voice can be heard through various organisations. 
As well as the BKPA,20 NKF21 and Kidney Research UK,33 
condition-specific patient groups have sprung up over the 
past few years, particularly for those with rare diseases. 
However, there is little published evidence for the research 
priorities of UK renal patients.
In 2013 Kidney Research UK undertook a survey46  
that asked people in the UK with a variety of kidney  
diseases what they considered to be the most  
important directions for renal research. 
Over 1,000 people responded.
From the questions posed, and despite the difficulties of living with a long-term 
condition that can negatively affect both quality and length of life,
the majority of these patients  
said they preferred to see  
research focus on an improved  
outlook for future kidney patients. 
They wanted studies to concentrate on cures and prevention as well as the causes 
and early detection of kidney diseases. They also highlighted the importance of 
finding new sources of organs for transplantation as well as improving the quality of 
life of people with kidney disease. 
Also in 2013, patients consulted on the Kidney Health:  
Delivering Excellence report47  said that 
research into self-management and  
finding better ways to alleviate the  
difficult symptoms of kidney failure 
were very important to them. Patient research preferences and priorities clearly  
need to be captured in future research, and a representative patient voice sought  
to inform the foci of renal research and the direction of research funding.  
In recent years patients have begun to be better informed about research. There 
is more of a focus on ‘lay summaries’ in research proposals; research groups are 
encouraged to include patients at all stages of the research development process. 
Information and opportunities to participate in research are presented and 
circulated by the BKPA (via its patient advisory group, website20 and social media),  
by the NKF (in its magazine Kidney Life)21 and via the KRUK website.48  A session at  
the 2013 NKF Conference on research generated a plea for more patient 
involvement, not only as trial participants but also on research steering groups;  
this group also highlighted the need for more effective communication of  
research findings and outcomes.
 46  https://www.kidneyresearchuk.org/patient-survey-2013-results
47  http://www.britishkidney-pa.co.uk/images/stories/downloads/Kidney-Health-Report.pdf
48  https://www.kidneyresearchuk.org/research/patient-and-carer-involvement
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2.1.2 Professional bodies
In compiling this report we received input from various 
professional bodies including the British Dietetic 
Association,49  BTS,19 NHSBT,30 NHS England,50 RA,16 the UK 
Renal Pharmacy Group,51  BRS,18 BAPN,17  UKKRC26 and the UK 
Renal Registry.28
As an overarching principle, 
kidney healthcare professionals  
believe that a UK renal  
research strategy should  
ultimately focus on outcomes  
that matter to patients, 
regardless of the cause or stage of kidney disease. It should 
enable world-class renal research to be performed from 
bench to bedside and from gene to populations. Furthermore 
there should be provision for high-quality qualitative and 
quantitative research. It should be across all age groups from 
the very young to the very old.
Consequently, clinical research should, wherever possible, 
include evidence from patients relating to quality of life and 
patient experience, not only to reflect what is important to 
patients but also to help assess risks and benefits from the 
patient perspective when making treatment decisions. There 
is also a specific need to evaluate the impact of all multi-
disciplinary renal-related healthcare professionals, such as 
pharmacists and dieticians, and the impact of self-care or 
self-management, on the patient experience and patient 
quality of life.  
There is a firm opinion that a  
strong foundation of relevant  
‘basic’ or ‘pre-clinical’ research  
is essential to inform future  
clinical research. 
For example, understanding the molecular biology underlying 
renal diseases enables the development of new therapies, 
as well as new tests to predict clinical outcomes. Related 
to this there is concern that we are in danger of losing the 
next generation of non-clinical renal researchers, which is 
currently a major issue throughout medically related science. 
It is therefore a high priority to develop and maintain the best 
possible environment to train future renal researchers, both 
clinical and non-clinical. 
There is also recognition  
of the importance of  
research into rare diseases, 
each of which may affect only a handful of patients, but which 
together affect a significant proportion of kidney patients. 
Better research into these diseases should lead to more 
equitable care, better treatments and better outcomes. 
The professional groups highlighted a number of specific 
research priorities encompassing the entire spectrum of 
kidney disease, although in terms of lives saved, 
acute kidney injury and dialysis  
are perceived to be the biggest  
impact areas and therefore  
important areas to invest in. 
However there is also a need to improve transplantation and 
CKD outcomes and to provide more support to explore the 
qualitative aspects of shared care models, which are an area of 
strength in the UK.
Clinical research priorities identified by these groups can be 
otherwise grouped into major themes: 
• Preventative care 
• Prevention of AKI
• Prevention of CKD
•  Prevention of the associated complications of CKD 
and dialysis such as cardiovascular and metabolic 
bone disease, 
which all lead to premature ill-health and death. 
A second theme is the  
pressing need to find better  
therapies for existing problems, 
for example advancement of perfusion technology to increase 
the availability of viable organs for transplant, and avoidance 
of nephrotoxic immunosuppression to help reduce kidney 
rejection and so extend transplanted organ survival. Within 
this theme there is a need to better understand the existing 
spectrum of response to established therapies, such as 
blocking the renin-angiotensin hormone system in proteinuric 
diseases. In other areas new therapies are required because 
there is either no proven treatment or no optimal treatment 
for the disease process; examples here include treatments 
for glomerulonephritis, acute kidney injury and antibody 
mediated transplant rejection. 
A further theme is the need  
to develop therapies with  
fewer and more acceptable  
side effects, particularly in the  
arena of immunosuppression, 
to avoid undesirable consequences such as  
diabetes, infection and cancer. There  
is also support for investigation  
into medication usage,  
efficacy and optimisation. 
49 http://www.bda.uk.com
50 http://www.england.nhs.uk
51 http://www.renalpharmacy.org.uk
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2.1.3 Renal research charities’ priorities
Three UK renal research charities made inputs into this  
section of the report: Kidney Research UK,33 KKR34 and the  
PKD Charity.22
Stakeholders within the charities themselves  saw the 
importance of  supporting a balanced  research portfolio,  
encompassing not only established investigators with high-
impact projects but also emerging investigators and/or those 
with more innovative but potentially riskier projects including 
technologies such as new imaging techniques, stem cell and 
other biological therapies. 
Research undertaken by  
scientists, clinicians and  
professionals allied to  
medicine should be  
equally encouraged. 
The wide spectrum of research priorities was recognised, 
ranging from basic research into the causes of renal disease 
(because a better understanding of disease mechanisms 
should help to develop therapies in the medium to long term), 
through to randomised clinical trials in order to balance the 
potential benefits against harm from medicines and other 
interventions. 
The importance of a  
strengthened integration  
between clinical  
investigators, basic  
scientists and industrial  
partners was highlighted. 
Particular areas of research interest encompass early  
pre-clinical work, such as defining the best animal models 
relevant to people with renal disease, exploring alternatives 
to animal models, where appropriate,52  and translating new 
biological insights into new treatments. 
Stakeholders also acknowledged 
that there is a second ‘translational gap’, 
namely quality improvement or  
the embedding of proven  
treatments into clinical  
practice, particularly at  
this time of unprecedented  
financial austerity within the NHS. 
Stakeholders wish to prioritise research into preventative 
measures such as earlier diagnosis, improved indicators 
for more prompt referral into specialist care, slowing the 
progression of chronic kidney disease, and prevention 
and treatment of its associated complications such as 
cardiovascular disease, bone disease and anaemia. There 
is also a significant appetite for more collaborative multi-
centre randomised clinical trials, for example those designed 
to test interventions to optimise early and long-term kidney 
transplant outcomes. 
Lastly there is enthusiasm  
for the application of  
modern genomics 
(e.g. whole genome sequencing and gene association studies) 
to understand renal disease both in populations and at the 
individual level (‘personalised genetics’). In particular this 
might include the application of genetics to define the primary 
disease for patients with ‘End Stage Renal Disease of unknown 
cause’, or studies to determine subgroups likely to benefit (or 
not) from particular therapies.
2.2 Evidence gaps
In every area of renal medicine there 
are knowledge gaps. In some cases 
these concern the mechanisms of 
how kidney diseases begin, how they 
progress and their complications. In 
turn, such insights should lead to new 
treatments. The relevance of specific 
animal models and their study being 
translatable to human disease, and 
finding suitable alternatives, are also 
important questions. In other areas 
there is insufficient evidence to be able 
to define the best care pathways, assess 
acceptability to patients, or ensure best 
outcomes. The track record of negative 
clinical trials reaching publication is poor 
and could be addressed by engaging in 
more feasibility studies, via organisations 
such as Alltrials53 but most importantly 
by increasing the number and quality of 
clinical trials carried out in the UK. 
The following list has been directly 
collated from our initial consultation, 
and has therefore been contributed to by 
all sectors within the renal community. 
Many of the evidence gaps highlighted 
here will require randomised trials to 
address them.
 Acute kidney injury:  
c   Suitable markers for earlier detection 
c   Better identification of those at risk
c   Novel therapies for prevention and to 
enhance recovery
c   Long-term outcomes and responses  
to therapy 
c  Optimal nutritional support
53 http://www.alltrials.net
Chronic kidney disease:
c   The impact of earlier diagnosis and 
intervention on outcomes
c   Better indicators for prompt referral to 
specialist care
c   Reducing cardiovascular risk
c   Better markers of progression, and prevention 
and treatment of systemic complications
c   Phosphate binders: long-term illness  
and mortality
c   Mechanisms of fibrosis 
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Dialysis:
c   Biological and psychosocial effects
c   Benefits of exercise
c   Nutritional research 
c   Understanding and reducing cardiovascular  
ill-health and mortality
c   Reducing complications of peritoneal dialysis
c   Vascular access and dialysis techniques
c   Technological innovations
Transplantation:
c   Classifying risk levels in transplant recipients 
c   Defining the best immunosuppressive regimen
c   Best perfusion technology
c   Effective therapies for chronic rejection
c   Best management of the highly sensitised kidney 
transplant recipient  
c   Management of antibody-mediated rejection 
c   Optimising transplant outcomes
c   Inducing tolerance to prevent rejection
Genetics and genomics:
c   Applying modern genomics (e.g. whole 
genome sequencing, association studies etc) 
to understand renal disease at the population 
level and at the individual (‘personalised 
genetics') levels 
c   Mining the genome to understand the 
molecular basis of many renal disorders, 
determining factors governing differential 
progression, responses to treatment etc.
c   Epigenetic modifiers in kidney disease
Patient experience, quality of  
care and quality of life:
c   Patient experience and its relationship to outcomes
c   Addressing the second ‘translational gap’ (quality 
improvement) of embedding proven interventions  
into clinical practice, in the context of a  
resource-limited NHS
c   Significantly different attitudes to organ donation 
within BAME communities
c   Additional questions regarding differences in clinical 
outcomes in this patient grouping and in different 
socio-economic groups in general
c   Patient reported outcomes – what patients want to 
know, what patients understand about what we tell 
them and how we should best communicate with them
c   Lack of evidence for treatments for many rare disorders
c   Making the leap into personalised medicine
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In this chapter we present the 
Recommendations underpinning 
our four strategic Aims that are 
designed to provide a framework for 
the sustainment of excellence in UK 
renal research. These were distilled 
from the challenges affecting 
research identified by researchers, 
clinicians, funders and patients in the 
renal community (Chapter 2). Each 
Recommendation is accompanied by 
a description of the related issues, 
followed by one or more suggested 
ways to achieve progress. They are 
not in a rank order. 
Chapter 3 
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Strategic Aim 1
To increase engagement of professionals, patients 
and the public with kidney research. 
Recommendation 1:
Develop a culture where every person with a renal disorder accessing 
any type of renal service (or their families and carers, where 
appropriate) is offered the opportunity to participate in research. 
•  We believe that all people with kidney disease should be able to participate in 
research, regardless of where they receive their care. Critically, access to clinical 
trials should be a routine part of discussions about treatment options. These ideas 
should apply equally to children and adults with kidney disease, and will require 
increased engagement of all staff encountering kidney patients and their families.
Commentary 1
Our experience, which is supported by our consultations, is 
that patients and their carers are keen to take part in research 
studies of all kinds. Such participation may involve the single 
contribution of a research sample, engagement with more 
complex protocols such as clinical trials, or participation in 
clinical research development.
We should strive to develop a culture similar to that in 
oncology, where enrolment of patients into research studies 
becomes the norm. There is a pressing need to further raise 
awareness and understanding of research among renal 
patients and their families in order to achieve a change in 
culture and secure a higher level of patient interest and 
engagement, both as advisors and as participants.  
 
The reverse of this coin is that ideally, every kidney 
condition has one or more eligible research studies (be they 
observational, interventional or laboratory-based) together 
with a local investigator. This would ensure that every patient 
has the opportunity to contribute to research locally, thereby 
both improving their own understanding of their disease while 
at the same advancing knowledge in that area. At present this 
is both disjointed and variable, somewhat akin to a ‘postcode 
lottery’ in that patients remote from ‘centres of excellence’ are 
generally disadvantaged.  
Taken together, these changes will mean that the footprint 
for renal research will grow, with a research culture embedded 
within all Renal Units. This will allow patients and their carers 
to participate in research more widely, give researchers 
better access to patients in local NHS Trusts, and enable more 
clinicians to engage in research activities.
Ways forward 1
•  More widespread adoption of a policy of Consent 
for Consent or Consent for Contact, where patients 
(or, where appropriate, their carers) give consent for 
researchers to access their medical records to check 
eligibility for future research studies. This would 
work most effectively in conjunction with a register 
of people who are willing for researchers to contact 
them to ask if they would like to take part in relevant 
current or future research projects. With additional 
resourcing, this register could form part of the UK 
Renal Registry.
•  A flexible and responsive regional Clinical Research 
Network resource of nurses/trials practitioners to 
engage and up-skill local multi-professional teams. 
•  Investment from academic renal units in one or more 
tenured research nurses/research managers would 
ensure greater agility to commit to both small-scale 
local studies as well as larger multi-centre studies 
(see Strategic Aim 3 on page 25).
•  Increased support for all patients and carers willing 
to become local ambassadors for research, ideally in 
every renal unit across the UK.
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Recommendation 2:
Increase and promote equitable access to research for minority 
groups with kidney disorders, including children and those from Black, 
Asian and Minority Ethnic backgrounds (BAME).
Commentary 2
Various issues that impede research relate more specifically 
to children than adults. Examples include adherence to 
treatment (especially for adolescents); effects of growth and 
puberty; difficulties applying data primarily obtained in adults; 
the high percentage of children whose underlying renal 
disorder is malformation of the urinary tract; and providing 
appropriate information so as to obtain appropriate consent.
A major gap both in paediatric nephrology (where many of the 
underlying conditions are rare) and in rare diseases in general 
is in translating research into patient benefit. This is partly due 
to the very small numbers at any one centre (and/or overall), 
and is related to a lack of consensus amongst paediatric 
nephrologists in this subspecialist field, and to difficulty in 
obtaining nationwide engagement.
Some research has already identified particular needs of BAME 
kidney patients in the UK and this has been summarised by 
the NBTA25. However, there are major issues that need both 
further research and action. For example, we do not know 
enough about why kidney diseases continue to be more 
common among BAME communities, including among those 
who are born in the UK, nor what can be done to reduce this. 
Attitudes to transplantation vary, despite actions taken to 
promote organ donation and transplantation within BAME 
communities as well as better understanding of what has 
worked in bringing about limited change to date.
The proportion of kidney  
patients from BAME  
background on dialysis or  
waiting for a transplant is  
disproportionate at around 
and will increase if we do not take action. Provision for 
patients from BAME backgrounds across the country varies 
greatly and this variation is unexplained. We need to focus 
future research activities on these issues and encourage 
funders and others to give this priority.
Ways forward 2
•  Development of the culture, as recommended for adults, 
whereby every child’s family is offered inclusion into a 
research study if possible.
•  Better development of high-quality paediatric clinical 
trials with national and international collaboration.
•  Ensuring that research opportunities and training are 
available for the paediatric multi-disciplinary team, to 
include study of all parts of a child’s psychological and 
physiological development.
•  Further investment in and development of the Rare Renal 
Disease registries. This is an obvious way to build critical 
research evidence, ensure best practice nationally and 
develop new therapeutic strategies. 
•  NBTA, charities and other patient organisations 
should raise awareness of the importance of research 
involvement within the kidney community and especially 
BAME community groups, and evaluate the barriers to 
such participation.
•  To increase BAME community participation, the UKKRC 
should work with NBTA and others to support and 
encourage research on BAME issues, raise researcher 
awareness, promote and monitor equitable recruitment 
opportunities (e.g. accommodating people with different 
languages, reading and writing skills, and needs) and 
develop guidance on best practice in recruiting BAME 
kidney patients. 
•  Positive action by research funders to promote research 
into BAME issues.   
25%
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Recommendation 3:
Create a national Kidney Biobank for collection and storage of 
biological samples from every kidney patient, to provide a strategic 
resource for fundamental and translational research.
Commentary 3
There is a pressing need for more extensive investment in and 
access to Biobanks (collections of biological samples e.g. DNA, 
tissue biopsies), of which there are currently in renal medicine 
a mere handful and most are diagnosis-specific. The research 
studies that were made feasible by the establishment of both 
the MRC-Kidney Research UK funded glomerulonephritis and 
also the Wellcome Trust/MRC funded vesicoureteric reflux UK 
DNA Banks began to illustrate the potential of biobanking  
in Nephrology. 
These early successes, which  
involved the collection of a  
few thousand samples, now  
need to be further developed  
and scaled-up. 
In the genomic and post-genomic eras, we must be able to 
generate and mine genomic, proteomic and metabolomic 
datasets relevant to renal disease in order to generate new 
therapeutic targets. We recognise that national genomic 
initiatives such as Genome England Limited (GEL) may well 
provide a solution for DNA and ‘omics’ samples, which are 
readily obtained and for which there is already storage and 
curating infrastructure. Other initiatives, such as the Wales 
Kidney Tissue Bank, the Rare Renal Disease Registry (RADAR) 
and the new Genomics England Clinical Interpretation 
Partnership (GeCIP) naturally feed into these aspirations. 
In future, we need to consider how to coordinate existing 
repositories as well as banking blood, urine and pathological 
samples from all participants in research (e.g. to be used to 
measure potential marker proteins and gene activity) and 
viable cells (e.g. to be used to generate stem cells capable of 
developing into kidney cells) – to be used as test beds for  
new therapies). 
Ways forward 3
•  Adoption of Open or Blanket Consent where patients give 
consent for their clinical material to be used in future 
research. Informed consent generally permits specific 
uses of clinical material, yet there are situations where 
material could be used more than once, even for as yet 
unknown research. Open or Blanket Consent is given 
only once, but covers any future use of the material. 
This is particularly important where new ideas or assays 
may emerge many years after individuals have given the 
consent and donated their clinical material; they may 
even have died in the meantime.
•  The development of the new national Biobanking facility 
in Milton Keynes (or similar) may present an immediately 
workable way forward for new collections.
•  Coordination of existing collections via a central register.
•  Adequate investment in observational or cohort studies 
with long-term follow up will be required to provide high 
quality clinical data alongside the collection of samples 
for biobanking.
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Recommendation 4:
To complete the research loop, better communicate the outcome of 
all kidney research to patients and the public in accessible language 
that they can understand.
Commentary 4
Effectively communicating the outcome of research  
projects to patients and the public is crucial not only to 
improve understanding of kidney function and disease,  
but also to enable patient involvement and participation  
in future studies. We believe that overall this needs  
significant improvement; 
many patients complain that  
they receive no or little  
feedback from the research  
activities in which they have  
participated voluntarily. 
We recognise that communicating the outcome of research 
requires special skills and funding, since adaptation of 
language is often needed, and a variety of media will need  
to be employed. 
Ways forward 4
•  ‘Kidney Charities Together’ (a group comprising the 
main kidney charities) is a suitable umbrella to develop 
guidance on how the outcome of research should be 
communicated to patients and consider what support 
it can provide in doing so. 
•  Funding to communicate the outcome of clinical 
research should be built into the research budget. 
Some organisations (e.g. the Wellcome Trust) already 
make such sums available.
•  Clear and open publication of centre-specific research 
activity would help patient awareness and enable them 
to make comparisons.
•  Review by the UKKRC of progress on the involvement 
of patients in research projects it supports and the way 
the outcome of these projects is communicated  
to patients.
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Recommendation 5:
Preserve support and funding of laboratory science, because new 
fundamental discoveries are the key to future improvements in health. 
•  As discussed in Chapter 1, the UK renal community can take pride in research 
successes concerning studies involving a very wide spectrum of topics from 
single molecules to whole populations, from quantitative to qualitative, and from 
observational to interventional. Preserving this variety is key to improving renal 
health and patient welfare.
Commentary 5
The journey to disease modifying therapies or preventative 
interventions can be long - the current ability of (for example) 
cancer researchers to initiate clinical trials is based on basic 
scientific discoveries made over a two-decade or more 
timespan. We therefore need to ensure that  
we continue to be world leading in  
basic science in order to develop  
the new therapeutic targets of  
the future 
which can be integrated into patient-centred research studies.
Of the various types of study relevant to renal patients, 
this Recommendation concerns those that seek firstly to 
understand the normal biology of the kidney (including how 
it is formed, grows and ages, and how it functions to maintain 
health) and secondly, those directed to understanding the 
nature of kidney diseases and how best to treat them. Without 
understanding these processes, it is unlikely that ideal 
therapies can be envisaged and applied. 
Cutting through these themes are a range of experimental 
techniques and approaches, all of which may provide critical 
‘pieces of the jigsaw’. Some of these are very ‘laboratory-
based’, while others involve direct studies of patients. A wide 
variety of basic science (e.g. developmental, cell and molecular 
biology, and physiology) and applied sciences (e.g. adult and 
paediatric nephrology, clinical genetics and health economics) 
may be involved. 
Furthermore, while there is much discussion about the use 
of animals (overwhelmingly mice and rats, but also fish and 
frogs) in research, renal research is likely to continue to 
need realistic animal models to work out the mechanisms 
of human disease and to act as test beds for new therapies. 
An excellent example of this is the ‘remnant kidney’ rat 
model of progressive renal disease in which the study of 
altered pressures within glomeruli led to the discovery that 
angiotensin II blockade could ameliorate kidney failure; 
such drugs are now a mainstay of treatment for people 
with damaged kidneys. In future, the more extensive use 
of biomarkers and non-invasive imaging techniques to 
monitor renal disease in pre-clinical models will allow a 
more sophisticated use of animals, and minimize numbers 
in experiments.
Ways forward 5
•  Setting up designated UK centres that can champion 
specific fields (e.g. genomics, animal research, 
pathophysiological mechanisms, clinical trials) 
and can act as hubs for these. An example is the 
recently-announced Genomic Clinical Informatics 
Panel (GeCIP) for nephrology, which is being led 
from University College London but has national 
membership.
•  Recognition in funding allocations that the eventual 
benefits to patients of pre-clinical studies may not 
be immediately apparent.
Strategic Aim 2 
Capitalise on the full spectrum of research approaches to ensure a 
well-balanced portfolio that includes underlying causes, prevention, 
treatment and impact. 
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Recommendation 6:
Increase the number and quality of clinical trials, to address evidence 
gaps and measure and determine best practice/treatment. 
Commentary 6
Randomised clinical trials remain the best method to test 
most interventions in medicine, and renal medicine is no 
exception. Indeed, such trials are essential for studying such 
complex and diverse populations. 
Despite some successes, it is well  
documented that nephrology lags  
behind most other specialties in  
the number and quality of clinical  
trials conducted,54 
and this situation must be addressed.
Lack of reliable trial evidence is one reason for the variation 
in care between kidney units that is discussed elsewhere 
(see Recommendation 8). For improvement science to play 
a role, we must prioritise randomised trials as a key method 
to establish best practice and then reduce inequalities by all 
units adopting the best practice guided by such trials. The 
SHARP trial has demonstrated that large randomised trials 
can change practice substantially and improve  
patient outcomes.55
While recognising that some interventions may not be 
amenable to randomisation and not all questions can be 
addressed immediately by trials, we must aspire to improve 
the evidence base in this fundamental way.
Some patients/carers are keen to contribute to research 
design and development and contribute to research bids and 
project boards, and this needs to be utilised more widely.56 
More often than not such volunteers are neither approached 
nor included, or are nominally included as a ‘box-ticking’ 
exercise. This is a highly undesirable situation, which if 
unchecked, risks Nephrology becoming a ‘research poor’ field 
in comparison with other specialities. 
Where appropriate, patients  
or carers should be genuinely  
involved from the earliest stages  
of study development so that their  
voice can be heard more effectively. 
Those who wish to sit on steering groups will clearly need 
training in how to be an effective member of a group in  
which they are going to be in a minority. 
Ways forward 6
•  Promote the strengths of UK nephrology (importantly 
the Renal Registry and other NHS registries, which 
allow efficient trial designs) and the NHS as an ideal 
venue for multicentre trials to industry to leverage 
funding to support activity in trials and related 
research.
•  Support and develop the existing infrastructure 
for clinical trials within the UK. The UKKRC 
has highlighted clinical research and fostered 
collaboration between units, but requires further 
support (e.g. a funded secretariat) to help it deliver 
further benefits.
•  Highlight clinical research and trials more to trainees 
(both clinical and in allied health professions) to 
encourage them to consider and seek training in such 
research. 
•  Develop dedicated training in clinical trials 
methodology, and embed this within existing training 
courses (e.g. the Advanced Nephrology course).
•  Appropriately train, support and reimburse patients 
and their carers who agree to take up positions on 
research study steering groups; this will require 
specific funding to be built into the overall budgets of 
such studies.
•  Develop a code of practice on how patients should be 
involved on research steering groups, both locally and 
nationally, led by patient-facing organisations (e.g. 
under the umbrella of ‘Kidney Charities Together’).
•  Funders to more comprehensively monitor and report 
the involvement of patients.
54  Strippoli, et al. J Am Soc Nephrol. 2004;15:411-9, Inrig et al. Am J Kid Dis. 2014;63:771-80
55  SHARP Collaborative Group. Lancet. 2011;377:2181-92
56  Navaneetha et al. Am J Kid Dis. 2015;65:641-643 
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Recommendation 7:
Embed commitment to robust and appropriate patient-focused 
qualitative research, to allow improvements in quality of care, health, 
quality of life and patient empowerment.
Commentary 7
The strength and value of qualitative research complementing 
data from quantitative clinical studies has long been 
recognised, particularly within NIHR funding streams, but this 
is often an underrepresented and poorly developed element 
of research bids. Identifying what works without exploring why 
and for whom provides a limited evidence base. 
Historically it cannot be denied that priority of access to 
larger renal charity money has been given to bench research 
and clinical trials at the expense of qualitative patient-
focused studies. Reasons for the perceived lack of importance 
associated with qualitative renal research until relatively 
recently are unclear. 
For research bids to be  
successful in the current  
competitive funding market,  
qualitative methods and  
expertise needs to be valued  
and integrated into bid  
development at an early stage. 
As with clinical trial development, co-producing bids with 
patients can assist this process. Organisations such as the 
Health Foundation state that expertise in patient/service user/
carer engagement must be included in bid applications.
Ways forward 7
•  Renal Clinical Study Groups should invest in and 
cultivate qualitative expertise within and across 
groups, to enhance the potential of research bid 
submission to a successful outcome.
•  To improve equity of research funding, research 
panels that assess grant applications must include 
members with the skills to understand and critically 
appraise the merits of robust qualitative methods. 
•  Further invest in applied clinical researchers trained 
from an early career stage in health services 
research methods.
•  Further develop patient-led research hubs, such as 
that in Cambridge.57 
57  http://www.cuh.org.uk/clinical-trials/cambridge-clinical-trials-unit-cctu/patient-led-research-hub
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Commentary 8
For many years the renal community has collated and 
monitored outcomes through the UK Renal Registry, but 
significant variations still exist among centres in the way 
care is delivered. There is unequal access to best treatment 
approaches for patients, which too often depends upon where 
people live. 
We will improve care for  
patients if we can reduce  
the research-practice gap  
and increase translation  
of research findings into  
clinical practice. 
However, improvement activities are often not backed by high 
quality evidence, and local context is a critical factor that 
may inhibit or facilitate the uptake and implementation of 
improvement work.
To raise standards in clinical practice, reduce unwarranted 
variations and increase equitable access for patients to best 
available treatment, more research that builds the evidence 
base supporting implementation of clinical improvements  
is needed.
To this end, NHS England and the Welsh Government’s 
Health Quality Improvement Partnership is currently funding 
a National CKD Audit whose objectives are to improve the 
identification of CKD patients in primary care, improve the 
management and outcomes of CKD patients and tailor the 
care of people with CKD to local care pathways.58 
As a community we should better promote the science of 
improvement work, in order to determine ‘what works’ and 
also better understand where and why interventions are 
effective. In this way we will be able to develop interventions 
that have transferable effectiveness and are based as much on 
evidence as the practices they seek to implement. 
Ways forward 8
•  Accept that the question of how to deliver reliable 
implementation of ‘best practice’ is a legitimate 
research question. This will require ownership and 
commitment by clinicians, units and renal care 
organisations to modifying practice based on best 
available evidence.
•  Continue to identify and expose variations in practice 
using the UK Renal Registry. 
•  Understand that evaluating complex, ‘system’ 
interventions requires different methods depending on 
the different treatments and conditions involved.  
•  Increase the emphasis on partnerships between 
academics with experience in improvement 
methodologies and front-line clinical staff, to enable 
the design, delivery and rigorous evaluation of complex 
interventions. 
•  Expand opportunities for and funding of Quality 
Improvement in kidney care. 
•  Develop collaborative networks of experts to promote 
and facilitate appropriate studies (such as cluster-
randomised trials) and trials, and promote the spread 
and uptake of the evidence they generate.59 
Recommendation 8: 
Build the evidence base (improvement science) that will 
reduce unwarranted variation in practice and increase 
equitable access for patients to best available treatment. 
58  http://www.hqip.org.uk/national-programmes/a-z-of-nca/kidney-chronic-kidney-disease-in-primary-care
59 Green CA BMC Med Res Methodology 2006;6:54; Ormandy et al J Ren Nursing 2015; 7:5
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Recommendation 9: 
Increase resources and mentorship to develop and maintain 
research skills among nurses, allied health professionals and 
clinicians to ensure high quality multi-disciplinary renal research. 
Commentary 9
It can convincingly be argued that Nephrology was the 
first specialty to truly embrace multi-professional working, 
which is crucial to delivering excellent renal clinical care. 
Similarly, research teams increasingly need multi-professional 
membership and allied health professional (AHP) team members 
(including nurses, social workers, pharmacists, physiotherapists, 
dietitians, counsellors, psychologists and technicians) can 
lead or play a vital research role. Good examples include the 
investigation of metabolic bone disease in CKD, optimal exercise 
regimes, nutrition questions and psychosocial counselling.
For AHPs, the problems associated  
with training and subsequent  
involvement in research are  
particularly challenging, and  
not limited to Nephrology. 
Post-qualification, research is not a mandated part of the 
progression pathway in any of these careers. Some undertake 
MSc or MPhil research and a very small number progress to a 
PhD. The relevant professional bodies do recognise the value of 
research in their competency frameworks, but many employers 
do not consider it to be a priority area when set against clinical 
responsibilities. In addition, few renal units have a resident team 
of research nurses, and many survive on short-term funding 
for individual projects. This disrupts continuity in longer-term 
project management and risks loss of ‘institutional memory’ 
when funding streams come to end and (for example) research 
nurses move on into other disciplines. Furthermore, research 
staff recruitment ‘lead time’ may delay the start of studies.
Clinicians wishing to do research generally begin by taking 
time out of their postgraduate clinical training, during which an 
external source of salary funding has to be found, usually by the 
award of a competitive research training fellowship from one 
of several funding bodies (e.g. KRUK, MRC, the Royal College of 
Surgeons or Wellcome Trust). This period may lead to the award 
of a higher degree (i.e. an MPhil, MD or PhD). However, 
increasing inflexibility in  
the training programmes  
of clinicians often prevents  
comprehensive research training. 
Thereafter, the majority returns to full-time clinical training 
and NHS consultant employment. For this cohort, pressure of 
clinical duties increasingly prevents release for research. Study 
leave is difficult to obtain. Dedicated research sessions are 
the exception, and are rarely supported by management who 
often see the clinical role as starting and finishing with service 
delivery. Left unchecked, this will eventually lead to depletion of 
senior nephrology clinical academic role models, with a cycle of 
further depletion in academic recruitment.
A motivated workforce is needed to instigate and  
manage research. 
The concept that research  
is the cornerstone of  
everything that we do and it  
should be everyone’s business  
is not generally supported  
across all professional and  
managerial sectors.
It takes considerable time to write a successful grant 
application, and to lead or support a research project and   
analyse the findings. It is almost impossible to do this well 
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•  Our future health depends on our ability to train and support the 
research leaders of the future, across all disciplines.
Strategic Aim 3 
Support the research training and career development of all 
contributors to renal research, to build sustainable research 
capability and capacity. 
Recommendation 10:
Improve support, training and career paths for  
non-clinical renal scientists in the academic sector. 
Commentary 10
Non-clinician ‘basic’ scientists are the bedrock from 
which much of the molecular, cellular, animal-based and 
epidemiological research derives. This group includes those 
working in laboratories, statisticians and epidemiologists. 
There is little in the way of career security for these 
researchers apart from the small percentage who achieve 
independence as group leaders/tenure-track post-holders. 
Those doing renal research are not unique in not having a 
properly developed and supported career structure – for the 
majority, the model is one of moving along a series of  
short-term contracts, the terms of which impose a lack of 
security that is a disincentive to continuing. This is a major 
problem across the spectrum of biomedical science.
In addition, individual  
laboratories are often  
hampered by the lack of  
long-term, significant  
infrastructure funding, 
necessitating the constant diversion of talent from research to 
writing applications for small segments of each programme. 
In addition, the lack of institutional support for professional 
technicians and lab managers means that academics can 
spend much time on lab maintenance tasks rather than larger 
issues and advances. 
Ways forward 10
•  We urge specialist funders to continue identifying 
and supporting excellent emerging researchers and 
research groups: there might otherwise be a danger of 
continually supporting a handful of centres.  
•  Conversely, academic centres need proactively to 
support their basic scientists who wish to conduct 
renal research.
•  Flexible support for those taking career breaks is 
essential.
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unless the investigator has dedicated research time. It is 
becoming increasingly uncommon for such protected time 
to appear outside of an ‘academic’ university contract.  Time 
allocation for NHS post-holders, either to lead research – if 
they have developed a particular area of expertise – or to act 
as local Primary Investigators in multi-centre studies, has been 
increasingly removed from NHS posts as it is not perceived to  
be profitable.
Ways forward 9
•  Research funders and NHS Trusts must be  
encouraged to develop training opportunities to  
invest in and enhance the research skills of the full 
multi-disciplinary renal team. 
•  An enhanced AHP fellowship initiative; those funded 
over recent years have progressed to, and continue  
to make a significant impact on, the renal  
research agenda.
•  Inclusion by relevant accreditation bodies of explicit 
requirements for research skills competencies in all 
renal-related health care professions.
•  For training-grade academic clinicians, there is a need 
to work collectively on new fellowship models where 
capacity can be increased through partnerships with 
industry, the Royal Colleges, and others including the 
MRC and Wellcome Trust.
•  For those with academic training who have returned to 
full-time clinical posts, and those in clinical posts who 
have the ability and desire to lead and participate in 
research, research skills acquired over periods of years 
should not be wasted.  All patients will not have the 
opportunity to participate in research without greater 
recognition of the importance of this group. The Royal 
Colleges and British Medical Association should make 
the case, to the NHS Confederation, NHS Employers and 
others, that more, not less, protected time for research 
is urgently needed.
•  The proposed re-introduction of AHP Fellowships 
would have a highly significant impact. At least one 
should be funded each year for the next decade. 
•  Funding support for those returning to research after a 
career break would help prevent attrition of talent.
Strategic Aim 4
Create a more open research culture to maximise  
cross-disciplinary and collaborative research.  
Recommendation 11:
Strengthen formal partnerships across disciplines, 
professional bodies and charities aligned with kidney disease, 
particularly in diabetes and cardiovascular disease.
•  To perform world-leading research it is critical that national collaborative projects and 
initiatives are established and supported across disciplines, and this applies to a wide 
spectrum from genomic studies to clinical studies and trials.
Commentary 11
While renal researchers are eligible for funding from Research 
Councils, Wellcome Trust and the NIHR, it goes without saying 
that this is an intense competition with other disciplines. 
Historically therefore, funding for renal research has relied to a 
great extent on specialty-specific charities such as  
Kidney Research UK, Kids Kidney Research, BKPA and BRS. 
These cannot usually provide sufficient funding to support 
a major multidisciplinary research idea to fruition over the 
medium to long term, particularly where co-morbidities are 
involved. Small-scale grants and the lack of seamless and 
sustainable support have in turn discouraged collaboration, 
leading to competition for access to clinical research material.
Engaged and effective teamwork  
is a core requirement to initiate,  
support and carry out high- 
quality research. 
The UK kidney community offers a formidable opportunity for 
collaborative working amongst clinicians within a relatively 
small specialty and with relatively similar practice. This is well 
demonstrated in the rare diseases arena, where national  
multi-disciplinary working groups have been developed. 
However, collaborative effort is not yet always sufficient to 
avoid diffusion of ideas and resources, or competition for 
access to clinical material. 
Effective research communication is also essential. It should 
allow all clinicians, researchers and patients to be aware of 
new funding initiatives they can bid for and also new studies 
in which they can participate and contribute. Currently, 
sometimes inadequate dissemination of relevant information 
means that individual researchers may be unaware of research 
opportunities and available support.
As a result, kidney research within the UK has on occasion 
been ad-hoc and opportunistic rather than structured and 
collaborative. Cooperation between centres rather than 
competition between them would significantly advance some 
fields of research. Better communication and collaboration 
among researchers would enable a more open culture and also 
discourage reporting bias. 
Importantly, kidney disease commonly co-exists with other 
conditions, particularly diabetes mellitus and cardiovascular 
disease. 
Up to 30% of people with  
diabetes have moderate to  
severe CKD. 
Powerful epidemiological data clearly demonstrate that CKD 
and an increase in albuminuria are both powerful independent 
risk factors for cardiovascular disease. The management of 
many other conditions is also complicated by the presence of 
kidney disease. 
Joined-up care that avoids ‘silo management’ is a well-
articulated (if often incompletely realised) concept in clinical 
practice. Thus we need to devote a greater effort to research 
that is integrated across these relevant specialties, not least to 
define and test appropriate quality markers relevant to patients 
with complex multi-morbidity. 
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Recommendation 12:
Build closer research links with industry to identify new 
therapeutic targets, develop collaborative clinical trials 
and research funding opportunities. 
Commentary 12
Historical mistrust between academia and industry has been 
dispelled in recent years, and 
there is a need to expand the  
renal portfolio of commercial  
research within the UK. 
An increased growth could markedly improve the research 
infrastructure in individual units, allowing staff expansion, 
and in turn, greater success with academic grants. This is  
also a major government target. It will also ultimately  
reduce the time that it takes for ideas to be translated into 
patient benefit. 
There are now recognised funding streams that are available 
for early and late academic-industrial collaborations through 
funding agencies such as MRC and Wellcome Trust. A good 
example is recent significant funding from Pfizer to carry on 
the work included in a recent ‘Progressive IgA nephropathy’ 
grant from the NIHR Rare Diseases Translational Research 
Collaboration funding stream.60 
Ways forward 12
•  Creation of firmer links between industry and the 
renal research community through collaborative 
meetings. The UKKRC and CSG leads are ideally placed 
to develop these relationships.
•  Ensure that the benefit of these links is clearly 
communicated to the academic and industrial world.
•  Intellectual property rights in this setting should be 
clearly defined, with involvement of those with specific 
expertise in this area; this will allow appropriate 
sharing of ownership between academic and  
industry partners. 
60  http://rd.trc.nihr.ac.uk/themes-2
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The climate is changing with  
the advent of new funding  
streams from the European  
Union, MRC and NIHR; the  
renal community needs rapidly  
to adapt to these opportunities.
Research integration should also include urology and other  
sub-specialties within surgery. Among many examples of the 
need to be more inclusive are complications and consequences 
of stone disease, unmet needs for transplantation research and 
post-operative AKI.
Ways forward 11
•  Establishment of a single high-quality, user-friendly 
UK national research communication portal through 
which all renal research activities can easily be 
accessed and used to identify new funding calls and 
studies. For clinical studies this could be curated by  
the UKKRC or the UKRR, and for preclinical ones, the 
RA or KRUK.
•  Greater recognition of the importance of collaboration 
with local NHS Trusts away from the traditional centres 
of excellence. Traditional academic centres may 
currently be leading research, but the contributions 
of participating sites must be better reflected in the 
budgeting of multi-centre studies.
•  Investment in smaller research units outside of  
London and the Home Counties to increase  
potential patient involvement. 
•  A clearly stated commitment by the professional 
associations supporting kidney disease, diabetes 
and cardiovascular disease to hold regular dedicated 
special interest sessions at their UK professional 
conferences would be helpful.
•  The UKKRC should expand and formalize its dialogue 
with research networks in diabetes and  
cardiovascular medicine.
•  A series of more specific research recommendations 
across the medical and surgical vascular disease 
spectrum should be agreed by the necessary patient 
and professional groups to define an appropriate scope 
for genuine interdisciplinary applications to NIHR and 
other funders.
Recommendation 13:
Work collectively towards a simpler, faster and more 
responsive pathway to ethical and regulatory approval, 
particularly for low-risk projects. 
Commentary 13
The diversity of approaches required for innovation is a 
constant challenge in large institutions such as government, 
universities, NHS Trusts and other agencies
hence the difficulty in navigating  
regulatory processes was an  
important barrier identified  
by respondents to our survey. 
While there have been many recent improvements, 
particularly since the introduction of the Integrated Research 
Application System, pathways for study approval would 
benefit from a swifter routing to shorten the time required to 
apply for and achieve Regulatory and Ethics approval. 
The current regulatory environment would benefit from 
adaptions that take into account the size and complexity of a 
study. Some NHS Trusts have been able to limit unnecessary 
bureaucracy and thus increase patient recruitment, 
particularly to low-risk studies. Work to support the spread of 
this good practice is essential.
Importantly, the current regulatory environment could 
be better adapted to consider Quality Improvement and 
Improvement Science projects, which occupy a space  
between service evaluation and human subjects research. 
Both of these areas of research are particularly in need of a 
flexible framework. 
In other areas legislation may benefit from review, one 
example being The Human Tissue Act 2004, which requires 
a license to remove material from a deceased person for 
research purposes. Whilst this provides important protection, 
as a consequence 
there has been a significant  
fall in the number of  
appropriately consented  
organs available for research. 
NHS Blood and Transplant report that partner organisations 
seek research material from abroad or move their studies to 
other countries where access to research material is  
less restricted. 
Ways forward 13
•  There should be a more collective, proactive 
approach to identify and drive legislative 
improvements in areas where new legislation 
could accelerate and enhance research. 
•  Multicentre studies have benefitted from recent 
changes in procedures for local approval; these 
pathways would benefit from continued efforts 
to improve efficiency.
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Conclusions
We hope that you have enjoyed reading this report. The 
stimulus to create it came from the Kidney Health: Delivering 
Excellence report that was published in 2013. One of the 
Ambitions articulated there was to develop a strategy for 
kidney research, and this is the result. 
The Steering Group first met in early 2014 and in the ensuing two years we have 
held several rounds of consultation with many stakeholders including patients, renal 
organisations detailed in Chapter 1.2 and Appendix 1, and various external bodies. 
Scoping exercises to learn stakeholders’ perspectives were followed by an  
opportunity to comment on the draft report, which yielded more than 70 responses 
and a revision. In these early and late phases we took into account all opinions and 
distilled them so that they could be represented in the main text and reflected in the 
Executive Summary. 
As we write this we are aware that 
each month, nearly 600 more people  
in the UK will reach ‘end stage kidney disease’,  
with lives that can only be saved by dialysis  
and transplantation. 
Hence research to understand why kidney disease occurs, and how best to prevent and 
treat it, is more important than ever before.
We believe that the current report is unique in encompassing the whole of ‘renal 
research in the UK’ and it is indeed a wide spectrum: from ‘blue skies’ basic biology 
studies, to pre-clinical and clinical trials, to research about quality of life and patients’ 
attitudes to their disease. Obviously, all these aspects are important and need to thrive.
This report should act as a springboard so  
that its Aims and Recommendations are now  
discussed in depth and then vigorously taken  
forward by renal and funding organisations,  
with help from patients and their families. 
Progress will need to be monitored and reviewed by an 
Implementation Board, preferably under the UKKRC umbrella and 
including representation of the full renal researcher spectrum, with 
formal review after two years. 
Finally, this report highlights actions required from champions of 
renal research in government and in industry to secure the future 
for high quality kidney research in the UK. 
The Steering Group
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Abbreviations
AHP Allied Health Professional
AKI Acute Kidney Injury
BAME Black, Asian and Minority Ethnic
BAPN British Association for Paediatric Nephrology
BKPA British Kidney Patient Association
BRS British Renal Society
BTS British Transplantation Society
CKD Chronic Kidney Disease
CRN Clinical Research Network
CSG Clinical Study Group
CSOS Chief Scientist’s Office Scotland
KRUK Kidney Research UK
KKR Kids Kidney Research
MRC Medical Research Council
NBTA National BAME Transplant Alliance
NHS National Health Service
NHSBT NHS Blood and Transplant
NIHR The National Institute for Health Research
NKF National Kidney Federation
RA The Renal Association
UKKRC UK Kidney Research Consortium
UKRR The UK Renal Registry
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What action next?
Suggestions for implementation would be welcome to:  
ukkrc@kidneyresearchuk.org  
Initial Discussion Session: UK Kidney Week 2016 (Birmingham)
?
1.  The Renal Association was founded in 1950. It 
has historically been regarded as the main professional 
organisation for the specialty. Initially a pre-clinical 
research-based grouping, it is active in promoting and 
disseminating research that may ultimately improve 
outcomes for people with kidney disease. It has grown to 
play an important role in clinical standards setting and 
in the education of clinicians and scientists interested in 
kidney disease. More recently it has become more active 
in issues around training of doctors and the planning and 
development of clinical services. The Association has 
become increasingly aware of the importance of healthcare 
delivery by a multi-disciplinary team and is affiliated with 
the British Renal Society, the umbrella organisation for 
healthcare and patient organisations with an interest in 
kidney disease.
2.  The British Association for Paediatric 
Nephrology was founded in 1972; it is committed 
to both high quality basic science and translational 
research related to children’s kidney diseases. It supports 
multicentre clinical trials across all areas of quantitative 
and qualitative paediatric research. One of the main initial 
reasons for its inception was to make clear that babies 
and children are not just tiny adults. Instead they require 
clinical care and advocacy from specially trained paediatric 
nephrologists and associated professionals to address their 
unique physiological and psychological needs. In 2010 The 
BAPN  became a direct partner of The Renal Association.
3.  The British Renal Society began as The British 
Renal Symposium in 1989 to promote formal dialogue 
between the many specialist groups supporting 
professionals involved in the care of people with kidney 
disease. It soon became apparent that such a strong 
multi-professional input could be of major benefit to the 
future development of renal care, by exerting influence 
at various levels including advancement of the evidence 
base, the commissioning process, and the formulation of 
policy. Since becoming the British Renal Society in 2001, 
the Society has grown substantially. Its core aims are: 
promotion of effective patient-centred multi-professional 
care to improve quality of life for patients, their families 
and carers; advancement of education in the area of renal 
disease and replacement therapy in the UK; funding and 
support of multi-professional research into kidney  
disease and its management. 
Appendix 1:  
Organisational components of UK renal research
4.  The British Transplantation Society  
is the professional voice of transplantation in the UK, 
representing all the varied disciplines in transplantation 
including clinicians, nurses, pharmacists, scientists 
involved in both basic research and in tissue typing 
laboratories, ethicists and other professionals allied to 
medicine.  Founded in 1972, BTS membership is open to 
all professionals working in the field of transplantation. 
It hosts an annual congress for its members, and also 
runs a variety of meetings throughout the year, including 
an annual ethics conference, living donation forum and 
training workshops.  
5.  Patient organisations There is a strong Patient, 
Carer and Public Engagement strategy within the renal 
community. Because kidney disease is frequently chronic, 
we engage with a large and mostly stable patient group 
who trust their clinicians and are interested in participating 
in research. Kidney patient charities are pivotal to the 
support of kidney research in the UK.  
a)  The British Kidney Patient Association was founded in 
1975 by the mother of a young kidney patient. This well 
established charity is working to improve the quality 
of life for adults and children with kidney disease by 
providing information, advice and support for those 
with kidney disease. Its programme of practical patient 
support includes a telephone counselling service and 
its role as the principal funder of the NKF/BKPA national 
Advocacy Service; grants to help patients and families 
to cover the costs of domestic bills; hospital travel; 
education and holidays; and financial support to kidney 
units throughout the UK to help improve kidney services 
and patient care. Patient-centred research and service 
evaluation sits at the heart of its efforts to improve 
health and social care policy and practice.
A. Professional and patient organisations
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b)  The National Kidney Federation is the national kidney 
charity run by kidney patients for kidney patients and 
was formed in 1978 to bring together local  
Kidney Patient Associations under a national umbrella. 
It is the largest kidney patient charity in the UK, 
representing nearly 25,000 kidney patients and has 55 
Kidney Patient Associations as its members. The NKF 
provides direct support and advice to patients, carers 
and others through a dedicated helpline and employs a 
team of nationally located advocacy officers to support 
more complex cases. It campaigns for improvements to 
renal provision and treatment for patients and works 
closely with the Departments of Health, NHS Blood and 
Transplant (NHSBT) and NHS England as well as the All 
Party Parliamentary Kidney Group consisting of over 106 
MPs and Peers. The NKF has a well-established system of 
communication with kidney patients and others through 
its magazine Kidney Life and through electronic and 
social media.
c)  There are many individual diagnosis-specific charities 
as well as patient/family support groups that aim to 
provide information, advice and support to patients 
and families and raise awareness, particularly in the 
rare diseases arena (see (9) below). These are often 
a powerful voice for clinical progress and research. 
Examples of such charities include The PKD  
(Polycystic Kidney Disease) Charity, Action for Alports 
and Atypical HUS.
d)  The National BAME (Black, Asian and Minority Ethnic) 
Transplant Alliance is a group, consisting of BAME 
groups, charities, NHSBT, the Department of Health and 
academics, which provides leadership and co-ordination 
of work with BAME communities in tackling barriers to 
organ and stem cell transplantation. 
6.  The UK Kidney Research Consortium  
was established in 2007 and is chaired in rotation by the 
Renal Association, Kidney Research UK and the British 
Renal Society. The overall aim is to facilitate the best 
collaborative clinical research for health in kidney disease. 
The consortium brings together interested researchers 
from the broad multi-disciplinary team into Clinical Study 
Groups (CSGs) with 12 different themes, as listed in Table A. 
Each group has a remit for generating a portfolio of clinical 
studies that can and should be undertaken in the UK where 
there is a clear need for more evidence. Membership of the 
CSGs includes representation from the multi-professional 
team and, wherever possible, trainees and patients/carers. 
Affiliated activities within the UKKRC include a reporting 
line from the Rare Diseases Committee of the Renal 
Association (see below); a clinical trials methodology 
training initiative for trainees; and more recently, it 
identified the need for an initiative to develop the science 
of Quality Improvement, to reduce variation in practice and 
facilitate spread and uptake of best practice.
7.  The NIHR Clinical Research Network Renal 
Disorders Specialty Group This group oversees 
research relating to renal medicine and supports a wide 
range of research studies for example in anaemia, chronic 
kidney disease and genetic disorders. A major remit is to 
review potential studies in renal disorders, particularly 
from industry, for inclusion on the UKCRN portfolio. All 
portfolio studies are eligible for infrastructure support 
from the UKCRN as well as additional support from the 
15 Local Clinical Research Networks that cover the length 
and breadth of England to ensure they are delivered 
successfully in the NHS for the benefit of patients.
Table A: UKKRC Clinical Study Groups
Acute kidney injury
Anaemia
Mineral and bone disorder
Cardio-renal
Chronic kidney disease progression and biomarkers
Cystic diseases
Exercise
Glomerulonephritis and vasculitis
Haemodialysis
Paediatric nephrology
Peritoneal dialysis
Transplantation
And a cross-cutting clinic trials network
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8.  The UK Renal Registry is a UK-wide organisation 
governed by the Renal Association, which led and 
continues to support its development. The UKRR is 
recognised as having one of the very few high-quality, 
comprehensive and secure clinical databases open to 
requests from researchers. It is principally funded by a 
capitation fee based on renal replacement therapy patient 
numbers and collects, analyses and reports on data from 
71 adult and 13 paediatric renal centres. Participation is 
mandated in England through the NHS National Service 
Specification. A major strength derives from the access 
to well-defined patient cohorts, allowing for the linking 
of basic and clinical research. Although there are large 
patient populations elsewhere (especially the US), access 
to those cohorts is often restricted due to competition 
between institutions and the lack of a national health 
service. The UK Renal Registry is indicative of the best of 
centralisation and coordination. The Registry has therefore 
become a major source of clinical data for the renal 
community, and with imminent technical upgrades, will 
become an even more useful tool for collecting outcomes 
data in observational and interventional research studies. 
It is currently expanding to include dialysis-requiring 
acute kidney injury patients and also houses the renal Rare 
Diseases Registry.
9.  Rare diseases A parallel initiative to the UKKRC was 
the establishment of a collection of Rare Disease Groups 
(RDGs). This initiative is a cornerstone of the Renal 
Association’s strategy for rare diseases. There are currently 
17 RDGs; each has an inclusive membership including 
patient, family or carer representatives. The groups are 
affiliated with the UK Registry for Rare Kidney Diseases 
(RaDaR), publishing online patient/clinician information 
and developing best practice care pathways. The next step 
is the establishment of group-specific national patient 
cohorts; this is being coordinated within the Renal Registry. 
RaDaR will provide a unique resource for future research in 
rare renal diseases. The chair of the Renal Association Rare 
Disease committee reports to the UKKRC.
61 http://www.saildatabank.com
10.  NHS Blood and Transplant This Special Health 
Authority was formed in October 2005 from the merger 
of the National Blood Service and UK Transplant. NHSBT 
is responsible for managing the National Transplant 
Database, which includes details of all donors and 
patients who are waiting for, or who have received, a 
transplant. NHSBT maintains the NHS Organ Donor 
Register, provides support for donor families and is 
responsible for the fair and unbiased matching and 
allocation of donated organs. In addition to setting 
national policies and guidelines for clinical care, NHSBT 
also undertakes audit and research, performs data 
analysis on organ transplant recipients, and provides 
support for external clinical studies and trials.
11.  Devolved nations 
a)  The Wales Kidney Research Unit was established 
in 2015 following a successful bid to the Welsh 
Government. It builds on established links between 
Welsh Renal Service providers, commissioners, 
patient groups and researchers, and provides core 
infrastructure support for renal studies in Wales, 
including central laboratory and tissue bank support 
(Cardiff) "big data" analysis in the internationally 
recognised Secure Anonymised Information Linkage 
databank (Swansea)61 and Health and Social Care  
analyst support (Bangor).
b)  Northern Ireland has a Renal Clinical Research Network, 
with wide engagement from nephrologists, covering all 
five acute hospital trusts. The Northern Ireland Health 
and Social Care Research and Development Division 
funds a part-time renal research nurse in each hospital 
trust (but unlike NIHR, no additional monies are provided 
to sites for patient recruitment into clinical trials).
c)  The Chief Scientist’s Office Scotland and NHS Research 
Scotland provide core funding for clinical research nurses 
on projects supported by eligible funders.
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B. Main funders
1.  Kidney Research UK was established in 1961, and is 
currently the leading national charity dedicated to funding 
renal research. It has played a major role in advancing 
the profile and importance of UK kidney research. Kidney 
Research UK funds research programmes and projects, 
together with individual clinician and non-clinician 
career awards ranging from intercalated BScs to Senior 
Fellowships. In 2014/15 it committed £5.1 million across 
59 awards. The charity works closely with, and co-funds 
with, professional organisations and industry, and 
recognises the benefits of collaborative partnerships. It has 
facilitated and overseen several academic-led research and 
quality improvement projects that have been supported by 
pharmaceutical partners. 
2.  Kids Kidney Research was originally set up as the 
Kidney Research Aid Fund in 1973, changing its name in 
2006. Originally funding research only at Great Ormond 
Street at a time when most childhood kidney diseases were 
poorly understood, KKR has grown to be a national funder 
to the tune of £0.5 million per year.
3.  The British Kidney Patient Association  
has over the last five years developed its research strategy 
and has its own grants programme disbursing over 
£250,000/year. This funds the Dr Tony Wing Fellowship, 
which is presently evaluating the impact of kidney failure 
on the lives of young people (managed by Kidney Research 
UK), and co-funds the annual joint multi-disciplinary 
Kidney Patient Research Partnership with the British Renal 
Society (see below) and RaDaR with Kidney Research UK. 
The BKPA also funds its own patient–centred research, and 
equipment and researchers needed to develop research 
studies of direct benefit to kidney patients.
4.  The British Renal Society has funded a programme 
of multi-disciplinary applied research since 2001, and 
since 2010 has developed sustainable joint research 
funding of around £150,000/year with the BKPA. The 
programme informs and impacts on the quality of patient 
care, service delivery and disease management, directly 
improving the lives of renal patients through evidence-
based practice. Grant funding provides opportunities for 
multi-professional early career researchers to establish 
a grant history, applied research experience and training 
from which to progress and capture sustained and 
significant research funding – a platform from which many 
clinical-based renal research leaders originated. A similar 
partnership between the BRS and Kidney Research UK has 
facilitated non-medical research fellowship funding.  
62 http://www.hrcsonline.net/pages/uk-health-research-analysis-2014
5.  The National Institute for Health Research 
supports translational and clinical renal researchers 
through a variety of funding streams including the 
Translational Research Collaboration Renal theme, 
Research for Patient Benefit, and Devices for Dignity 
schemes. These enable investigations ranging from rare 
disease deep phenotyping to qualitative research to 
technological development for patient benefit.
6.  The Health Foundation has played an important role 
in raising the profile of improvement science in the kidney 
community and has funded several improvement projects 
spanning the kidney care pathway, from primary care 
through to End Stage Renal Disease.
7.  In Scotland, the Chief Scientist’s Office grants funds 
to both clinical and non-clinical research projects and has 
fellowships for clinicians in training and in the Scottish 
Senior Clinician Scientist scheme. Funding support is also 
available from NHS Research Scotland (NRS) to permit  
NHS consultants to undertake research under  
the NRS fellowship scheme. Nephrology has generally  
been successful in attracting funding in these  
competitive schemes. 
8.  Other funding bodies include the Medical 
Research Council, Wellcome Trust, British 
Heart Foundation and the Royal College of 
Surgeons Many renal researchers have been awarded 
grants from major government and charity funding bodies, 
whose programmes include personal Fellowship funding as 
well as programme-based and project grants. The overall 
amounts available are much higher, but renal applicants 
are in open competition with other eligible applicants from 
all specialties, and renal research receives only a very  
small percentage.62
9.  In Industry, various companies in the pharmaceutical 
sector have been major supporters of trials in Nephrology. 
Current and recent examples include Vifor Pharma 
(PIVOTAL study) and Alexion (Eculizumab study).
10.  The European Union is another main funder. In 
January 2014 the EU launched its largest ever Research 
and Innovation funding programme, ‘Horizon 2020’, its 
eighth Framework Programme. The available budget is 
over £63 billion (€80 billion) and covers a seven-year 
period (2014-2020). The funds are allocated through a 
competitive process, in which the UK traditionally has 
fared very well, receiving a fifth of all previous grants.
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Drugs and interventions  
to treat CKD and its  
complications
The UK renal community has worked hard to develop 
approaches to answer well-defined questions of clinical 
importance in large clinical trials. Recently completed and 
ongoing studies include: 
•  The Study of Heart and Renal Protection (SHARP) trial, which 
has influenced international guidelines for the use of lipid 
lowering therapy in people with chronic kidney disease63
•  Determining the benefits of drugs which affect the renin 
angiotensin system in people with advanced kidney disease 
(STOP-ACEi)64  
•  Investigating the optimum amount of intravenous iron that 
kidney patients on dialysis should receive (PIVOTAL)65 
•  Working out the dose of steroids in children with nephrotic 
syndrome that cause the fewest side effects (PREDNOS, 
PREDNOS2)66  
•  Determining the best drug treatments for people who 
have inflammation of kidney blood vessels (vasculitis), a 
programme that links the UK with other European countries67 
•  Evaluation of the risks and benefits of renal artery stenting to 
improve kidney function (ASTRAL trial)68 
•  The adoption of eculizumab, a highly effective drug to treat 
atypical haemolytic uraemic syndrome69 
63 Haynes R et al J Am Soc Nephrol 2014;25:1825-33
64 Aimun K. et al Nephrol. Dial. Transplant 2010;25: 3977-3982
65 http://www.kidneyresearchuk.org/pivotal
66  http://www.birmingham.ac.uk/research/activity/mds/trials/bctu/trials/ 
renal/prednos/index.aspx
67 Jones RB et al Ann Rheum Dis 2015;74:1178-82
68 ASTRAL investigators N Engl J Med 2009; 361:1953-1962
69 Sheerin N et al QJM Epub ahead of print PMID: 25899302
70 Stevens PE et al Kidney Int 2007;72: 92–99
71 Lusignan SD et al Kidney Int. 2013;84:609-20 
72  Gould DW, Nephrology 2014;19:519-27;  
Greenwood SA, et al. J Ren Care 2014;40:219-26
73 Jayanti A et al Nephrol Dial Transplant 2013;28:2612-2620
74 Thomas N. Brit J Renal Med 2011;16:19-22
75 Burton JO et al Clin J Am Soc Nephrol 2009;4:1925-1931
76  Okamoto I et al Clin J Am Soc Nephrol. 2015;10:120-6;  
Da Silva Gane M et al Clin J Am Soc Nephrol 2012;7:2002-9
77 Shroff R  et al Clin J Am Soc Nephrol 2012;7:216-223
78 Lindley E et al Nephrol Dial Transplant 2012;27(Suppl 2):ii48–ii49
79 Wileman V et al Ann Behavioral Med 2014;4: 275-81
Care of people with CKD  
prior to and on dialysis
•  Unravelling the epidemiology of CKD in the UK70 
•  Exploring how to empower primary care to deliver better 
quality care to people with CKD (the QI-CKD trial)71 
•  Research related to the importance of exercise for patients 
with CKD or on dialysis72  
•  Research related to the advantages of home haemodialysis73 
•  Projects such as ENABLE-CKD demonstrating the 
importance of patients participating in their own renal care74 
•  Research to minimise the harmful effects of dialysis on  
other organs75  
•  Exploring conservative care for CKD in the community76 
•  Improving vitamin D balance in  
children with CKD77 
•  Body composition monitoring in  
children and adults78  
•  Novel behaviour change  
interventions79  
Appendix 2:  
The impacts of UK Renal Research
We began the process of formulating this strategy document by 
asking a wide range of stakeholders to provide examples of recent 
research that they consider has had (or will have) the most impact. 
While a complete list is beyond the scope of this document, the 
responses received included a number of notable research studies  
in which the UK has led the way, which are listed here.
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80  Ravanan R et al BMJ 2010;341:c3451
81 Calestani et al Nephrol Dial Transplant. 2014;29:2144-50 
82 Chan W et al J Ren Nutr 2014;24:1-12
83 Udayaraj U et al Transplantation 2012;93:610-616
84 Ding WY et al J Am Soc Nephrol 2014;25:1342-48
85 The 3C Study Collaborative Group Lancet 2014;384:1684–90
86 Welsh GI et al Cell Metab 2010;12:329-340
87 Randles M et al J Am Soc Nephrol epub ahead of print PMID: 25896609
88  Bech AP et al Clin J Am Soc Nephrol 2015;7:1386-1392;  
Goodship TH et al Mol Immunol 2015;52:200-206
89  Dessapt-Baradez C et al J Am Soc Nephrol 2014;25:33-42;  
Huang JL et al J Am Soc Nephrol 2016;27:69-77
90 Fresquet M et al J Am Soc Nephrol. 2015;26:302-13
91  Stuart HM et al J Am Soc Nephrol 2015;26:797-804;  
Clissold RL et al Nat Rev Nephrol 2015;11:102-112
92 http://www.rarerenal.org
93 McCarthy HJ et al Clin J Am Soc Nephrol 2013;8:637-648
94 Simms RJ et al Transplantation 2015;99:1023-9
Kidney transplantation 
•  Pinpointing inequalities in access to kidney transplantation80 
•  Assessing patient attitudes towards transplant listing: the 
ATTOM study81  
•  Obesity and kidney transplantation and the role of 
nutritional intervention in kidney transplant outcomes82 
•  A UK Renal Registry analysis exploring the relationship 
between socio-economic status, ethnicity and access to 
living donor kidney transplantation83 
•  Predicting recurrence of kidney  
disease after transplantation84  
•  Working out the best drugs to  
prevent rejection of renal  
transplants: the 3C study85  
Genetic causes of renal disease
•  Explaining why people are sometimes born  
with abnormal kidneys and urinary tracts91 
•  The discovery of genetic causes of a wide  
variety of renal diseases (including  
tubulopathies, podocyte disorders),  
leading to a better definition of clinical  
disease, the facilitation of family  
counselling and insights into basic  
biological processes92 
•  Pioneering comprehensive gene testing  
in people with nephrotic syndrome93 
•  Using genetic testing to work out  
whether relatives of patients with polycystic 
kidneys should donate organs94 
The biology of renal diseases
These examples include cellular and  
developmental biology, and genetic 
studies. A subset have used animal 
studies to better understand how the 
kidney works in health and disease.
•  Showing how insulin affects cells in  
the kidney’s glomeruli, which filter 
blood to make urine86 
•  Showing how racial background, and whether one is male  
or female, affects the molecular make-up and structure of 
the glomerulus87  
•  Demonstrating that antibodies 
produced by patients may harm their 
own kidneys and cause renal failure88  
•  Showing that ‘growth factors’ can be 
used as novel treatments to slow down 
the growth of kidney cysts and diabetic 
kidney disease89 
•  Demonstration of the cause of most cases of  
membranous nephropathy90 
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